February 19, 2009 / 4:46 PM / 11 years ago

US FDA reviews deaths of Genentech Raptiva patients

WASHINGTON, Feb 19 (Reuters) - U.S. regulators have received three confirmed reports of a serious brain infection in patients treated with Genentech’s DNA.N psoriasis drug Raptiva, the Food and Drug Administration said on Thursday.

The FDA said it also was aware of a fourth possible case of progressive multifocal leukoencephalopathy (PML) in a Raptiva patient. Two of the patients with confirmed PML died, as did the patient with a possible case, the agency said.

The FDA said it was reviewing the information and “will take appropriate steps to ensure that the risks of Raptiva do not outweigh its benefits.” (Reporting by Lisa Richwine, editing by Dave Zimmerman)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below